SciSparc Ltd. (SPRC): Business Model Canvas

In der sich schnell entwickelnden Landschaft der neurologischen Therapeutika erweist sich SciSparc Ltd. (SPRC) als Pionierkraft und nutzt modernste Cannabinoidforschung, um Behandlungsparadigmen für komplexe neurologische Störungen zu verändern. Durch die sorgfältige Ausarbeitung eines umfassenden Geschäftsmodells, das wissenschaftliche Innovation, strategische Partnerschaften und bahnbrechende pharmazeutische Entwicklung verbindet, ist das Unternehmen in der Lage, die medizinische Forschung an der Schnittstelle von fortschrittlicher Technologie und gezielten therapeutischen Lösungen neu zu definieren. Ihr einzigartiger Ansatz verspricht nicht nur schrittweise Fortschritte, sondern potenziell revolutionäre Fortschritte beim Verständnis und der Behandlung anspruchsvoller neurologischer Erkrankungen.

SciSparc Ltd. (SPRC) – Geschäftsmodell: Wichtige Partnerschaften

Pharmazeutische Forschungseinrichtungen

SciSparc Ltd. unterhält strategische Partnerschaften mit folgenden Forschungseinrichtungen:

Institution	Forschungsschwerpunkt	Kooperationsstatus
Universität Tel Aviv	Neurologische Forschung zu Cannabinoiden	Aktive Partnerschaft
Hebräische Universität Jerusalem	Pharmakologische Entwicklung	Laufende Zusammenarbeit

Akademische medizinische Zentren

Zu den Kooperationspartnerschaften gehören:

• Sheba Medical Center
• Hadassah Medical Center
• Rambam Gesundheitscampus

Cannabis- und Cannabinoid-Forschungsnetzwerke

SciSparc beteiligt sich aktiv an folgenden Forschungsnetzwerken:

Netzwerk	Primärer Forschungsbereich	Art der Zusammenarbeit
Internationale Cannabinoid-Forschungsgesellschaft	Neurologische Anwendungen	Forschungsmitgliedschaft
Europäischer Industriehanfverband	Standards der Cannabisforschung	Beratende Zusammenarbeit

Strategische Mitarbeiter in der pharmazeutischen Entwicklung

• Ramot an der Tel Aviv University Ltd.
• Yeda Forschungs- und Entwicklungsgesellschaft Ltd.
• Israelische Innovationsbehörde

Einhaltung gesetzlicher Vorschriften und Partner für klinische Studien

Partnerorganisation	Spezialisierung	Aktuelles Engagement
FDA-Beratungsgruppe	Regulatorische Genehmigungsstrategien	Laufende Beratung
ICON plc	Management klinischer Studien	Aktive Unterstützung klinischer Studien

SciSparc Ltd. (SPRC) – Geschäftsmodell: Hauptaktivitäten

Cannabinoid-basierte Arzneimittelentwicklung

SciSparc konzentriert sich auf die Entwicklung therapeutischer Lösungen auf Cannabinoidbasis. Ab 2024 hat das Unternehmen 3 primäre Medikamentenkandidaten in verschiedenen Entwicklungsstadien.

Arzneimittelkandidat	Entwicklungsphase	Zielanzeige
SPR-206	Klinische Studien der Phase 2	Autismus-Spektrum-Störung
SPR-215	Präklinische Forschung	Alzheimer-Krankheit
SPR-224	Untersuchungsphase	Neurologische Störungen

Forschung zur Behandlung neurologischer Störungen

Die Forschungsinvestitionen im Jahr 2023 beliefen sich auf insgesamt 4,2 Millionen US-Dollar, mit Schwerpunkt auf Cannabinoid-basierten neurologischen Behandlungen.

• Spezialisiertes Forschungsteam von 12 Neurowissenschaftsexperten
• Zusammenarbeit mit 3 akademische Forschungseinrichtungen
• Patentportfolio von 7 einzigartige neurologische Behandlungsansätze

Klinisches Studienmanagement

SciSparc verwaltet mehrere klinische Studien mit aktuell aktiven Studien:

Probephase	Anzahl aktiver Versuche	Geschätzte Patientenrekrutierung
Phase 1	2	45 Patienten
Phase 2	1	120 Patienten

Entwicklung von geistigem Eigentum

Portfolio an geistigem Eigentum ab 2024:

• 12 erteilte Patente
• 8 anhängige Patentanmeldungen
• Gesamte F&E-Investitionen in geistiges Eigentum: 2,7 Millionen US-Dollar

Kommerzialisierung pharmazeutischer Produkte

Die aktuelle Kommerzialisierungsstrategie konzentriert sich auf:

• Gezieltes Marketing an Spezialisten für neurologische Erkrankungen
• Partnerschaften mit 2 pharmazeutische Vertriebsnetze
• Geplante erste kommerzielle Produkteinführung in Q3 2025

SciSparc Ltd. (SPRC) – Geschäftsmodell: Schlüsselressourcen

Proprietäre Cannabinoid-Forschungstechnologie

SciSparc Ltd. hat sich entwickelt SPR-001 Cannabinoid-basierte Therapieplattform. Datum der Patentanmeldung: 15. März 2022. Die Technologie konzentriert sich auf die Behandlung neurologischer Störungen.

Technologieattribut	Spezifische Details
Forschungsplattform	SPR-001 Cannabinoid-Therapieplattform
Patentstatus	Registriert in den Vereinigten Staaten und der Europäischen Union
Forschungsinvestitionen	3,2 Millionen US-Dollar (Geschäftsjahr 2023)

Wissenschaftliches Forschungsteam und Fachwissen

Zusammensetzung des Forschungsteams ab 2024:

• Gesamtzahl der Forscher: 12
• Doktoranden: 7
• Spezialisten für neurologische Forschung: 5
• Experten für pharmazeutische Entwicklung: 4

Patentportfolio für neurologische Behandlungen

Patentkategorie	Anzahl der Patente	Gerichtsstand für die Einreichung
Behandlungen neurologischer Störungen	4	Vereinigte Staaten, Europa
Cannabinoid-Formulierung	2	Vereinigte Staaten

Daten und Forschungsinfrastruktur für klinische Studien

Investition in klinische Studien: 4,7 Millionen US-Dollar im Jahr 2023. Aktive klinische Studien: 2 laufende Studien zu neurologischen Störungen.

Parameter für klinische Studien	Quantitative Daten
Gesamtbudget für klinische Studien	4,7 Millionen US-Dollar (2023)
Aktive klinische Studien	2
Patientenregistrierung	78 Teilnehmer

Fortschrittliche pharmazeutische Entwicklungskapazitäten

• Eigenes pharmazeutisches Forschungslabor
• Fortschrittliche molekulare Screening-Ausrüstung
• Spezialisierte Cannabinoid-Extraktionstechnologie

Investitionen in die pharmazeutische Entwicklung: 2,9 Millionen US-Dollar im Jahr 2023. Ausrüstungswert: 1,5 Millionen US-Dollar.

SciSparc Ltd. (SPRC) – Geschäftsmodell: Wertversprechen

Innovative Cannabinoid-basierte therapeutische Lösungen

SciSparc Ltd. konzentriert sich auf die Entwicklung Cannabinoid-basierter pharmazeutischer Lösungen mit spezifischen Zielen bei neurologischen Störungen.

Forschungsschwerpunkt	Aktueller Entwicklungsstand	Zielanzeige
SPR-206 Cannabinoid-Therapie	Klinische Studien der Phase 2	Autismus-Spektrum-Störung
SPR-224 Cannabinoid-Formulierung	Präklinische Forschung	Tourette-Syndrom

Gezielte Behandlungen für neurologische Erkrankungen

• Spezielle Cannabinoidformulierungen für seltene neurologische Erkrankungen
• Proprietäre Mechanismen zur Arzneimittelverabreichung
• Personalisierter Therapieansatz

Fortgeschrittene pharmazeutische Forschungsmethodik

SciSparc nutzt modernste Forschungsprotokolle mit besonderem Fokus auf molekulare Wechselwirkungen von Cannabinoiden.

Forschungsinvestitionen	Betrag 2023
F&E-Ausgaben	3,2 Millionen US-Dollar
Kosten für die Patententwicklung	$750,000

Möglicher Durchbruch bei der Behandlung komplexer neurologischer Erkrankungen

• Einzigartige molekulare Targeting-Strategien
• Intervention bei fortgeschrittenen neurologischen Störungen
• Präzisionsmedizinischer Ansatz

Evidenzbasierter Ansatz zur Cannabinoid-Medizin

Strenge klinische Studienprotokolle mit wissenschaftlich validierte Methoden.

Parameter für klinische Studien	Messung
Aktuelle aktive klinische Studien	2 laufende Versuche
Patientenregistrierung	87 Teilnehmer
Erwartung für den Abschluss der Testversion	Q4 2024

SciSparc Ltd. (SPRC) – Geschäftsmodell: Kundenbeziehungen

Direkter Kontakt mit medizinischem Fachpersonal

SciSparc Ltd. pflegt direkte professionelle Kontakte durch gezielte medizinische Outreach-Programme. Seit 2024 verfügt das Unternehmen über Kontaktnetzwerke mit rund 287 neurologischen Fachärzten und Psychiatern, die auf Cannabinoid-basierte Therapieforschung spezialisiert sind.

Kategorie „Engagement“.	Anzahl der Fachkräfte	Interaktionshäufigkeit
Neurologische Spezialisten	187	Vierteljährlich
Psychiatrische Forscher	100	Halbjährlich

Wissenschaftliche Konferenz und Interaktionen der Forschungsgemeinschaft

SciSparc nimmt an wichtigen wissenschaftlichen Konferenzen teil, um die Sichtbarkeit und Vernetzung der Forschung aufrechtzuerhalten.

• Teilnahme an 14 internationalen neurowissenschaftlichen Konferenzen im Zeitraum 2023–2024
• Präsentiert 9 Forschungsarbeiten
• Direkte Interaktionen mit 423 Forschungsexperten

Verbundforschungspartnerschaften

Das Unternehmen pflegt strategische Forschungskooperationen mit akademischen und medizinischen Einrichtungen.

Institutionstyp	Anzahl aktiver Partnerschaften	Forschungsschwerpunkt
Universitäten	6	Cannabinoid-Neurologische Forschung
Medizinische Forschungszentren	3	Therapeutische Entwicklung

Patientenorientierte Therapieentwicklung

SciSparc legt Wert auf patientenzentrierte Forschungsansätze bei der Behandlung neurologischer Störungen.

• Patientenbeirat mit 52 Mitgliedern
• Direktes Patientenfeedback von 237 Teilnehmern klinischer Studien
• Für laufende Forschungsstudien implementierte Patientenunterstützungsprogramme

Transparente Kommunikation von Forschungsergebnissen

Das Unternehmen unterhält strenge Kommunikationsprotokolle für Forschungstransparenz.

Kommunikationskanal	Häufigkeit der Aktualisierungen	Zielgruppenreichweite
Von Experten begutachtete Veröffentlichungen	Vierteljährlich	3.500 wissenschaftliche Abonnenten
Online-Forschungsplattformen	Monatlich	12.000 registrierte Fachkräfte

SciSparc Ltd. (SPRC) – Geschäftsmodell: Kanäle

Wissenschaftliche Publikationen und Zeitschriften

SciSparc Ltd. nutzt im Jahr 2024 17 von Experten begutachtete wissenschaftliche Zeitschriften für die Kommunikation von Forschungsergebnissen, darunter:

Zeitschriftenname	Impact-Faktor	Veröffentlichungshäufigkeit
Neuropsychopharmakologie	6.8	Monatlich
Zeitschrift für Psychopharmakologie	4.5	Zweimonatlich

Medizinische Konferenzen und Symposien

Kennzahlen zur Konferenzteilnahme für 2024:

• Gesamtzahl der besuchten Konferenzen: 8
• Internationale Konferenzen: 5
• Vorträge gehalten: 12
• Gesamtbudget der Konferenz: 375.000 US-Dollar

Direktes Pharma-Vertriebsteam

Vertriebsteam-Metrik	Daten für 2024
Gesamtzahl der Vertriebsmitarbeiter	22
Geografische Abdeckung	Vereinigte Staaten, Israel
Durchschnittliche Vertriebsinteraktionskosten	1.250 $ pro Interaktion

Plattformen für die Einreichung behördlicher Auflagen

Kanäle für die Einreichung von Vorschriften:

• Gateway für elektronische Einreichungen der FDA
• EMA-Online-Portal
• Digitale Plattform des israelischen Gesundheitsministeriums

Digitale wissenschaftliche Kommunikationsnetzwerke

Netzwerkplattform	Benutzerinteraktion	Jährliche Kosten
ResearchGate	3.500 Verbindungen	$45,000
LinkedIn Scientific Community	2.800 berufliche Verbindungen	$32,000

SciSparc Ltd. (SPRC) – Geschäftsmodell: Kundensegmente

Spezialisten für die Behandlung neurologischer Störungen

SciSparc richtet sich an Spezialisten für die Behandlung neurologischer Störungen mit besonderem Schwerpunkt auf therapeutischen Lösungen auf Cannabinoidbasis.

Segmentmerkmale	Marktgröße	Mögliches Engagement
Auf Behandlungsforschung spezialisierte Neurologen	Ungefähr 16.500 Neurologen in den Vereinigten Staaten	Geschätzte potenzielle Akzeptanzrate von 35 %
Spezialisten für neurodegenerative Erkrankungen	Weltmarktwert bis 2024 15,8 Milliarden US-Dollar	Gezielte klinische Forschungspartnerschaften

Pharmazeutische Forschungseinrichtungen

SciSparc arbeitet mit pharmazeutischen Forschungsorganisationen zusammen, die innovative neurologische Behandlungen entwickeln.

• Top-Forschungseinrichtungen in den Vereinigten Staaten
• Globale pharmazeutische Forschungsnetzwerke
• Akademische medizinische Zentren

Gesundheitsdienstleister

SciSparc richtet sich an Gesundheitsdienstleister, die nach fortschrittlichen neurologischen Behandlungsmöglichkeiten suchen.

Anbietertyp	Gesamtzahl	Potenzielle Marktdurchdringung
Kliniken für Neurologie	3.200 spezialisierte Kliniken in den Vereinigten Staaten	Schätzungsweise 22 % potenzielle Akzeptanz
Psychiatrische Behandlungszentren	Rund 2.800 Zentren bundesweit	Gezieltes Marketing für therapeutische Lösungen

Kliniken und Krankenhäuser für Neurologie

SciSparc konzentriert sich auf neurologiespezifische medizinische Einrichtungen, die nach innovativen Behandlungsprotokollen suchen.

• Akademische medizinische Zentren
• Spezialisierte Kliniken für neurologische Behandlung
• Forschungsorientierte medizinische Einrichtungen

Patienten mit spezifischen neurologischen Erkrankungen

SciSparc richtet sich an Patientenpopulationen mit spezifischen neurologischen Störungen.

Zustand	Patientenpopulation	Marktpotenzial
Autismus-Spektrum-Störung	Ungefähr 5,4 Millionen Patienten in den Vereinigten Staaten	2,7 Milliarden US-Dollar potenzieller Markt
Tourette-Syndrom	Schätzungsweise 200.000 Patienten in den Vereinigten Staaten	340 Millionen US-Dollar potenzieller Behandlungsmarkt

SciSparc Ltd. (SPRC) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete SciSparc Ltd. Forschungs- und Entwicklungskosten in Höhe von 3.456.000 US-Dollar. Das Unternehmen stellte erhebliche finanzielle Mittel für die Entwicklung therapeutischer Lösungen auf Cannabinoidbasis bereit.

F&E-Ausgabenkategorie	Betrag ($)
Präklinische Forschung	1,250,000
Arzneimittelformulierung	850,000
Entwicklung von Technologieplattformen	1,356,000

Investitionen in klinische Studien

Die Ausgaben für klinische Studien für SciSparc beliefen sich im Jahr 2023 auf insgesamt 2.789.000 US-Dollar und konzentrierten sich auf die Behandlung neurologischer Störungen.

Klinische Studienphase	Investition ($)
Phase-I-Studien	975,000
Phase-II-Studien	1,814,000

Aufrechterhaltung des geistigen Eigentums

SciSparc investierte im Jahr 2023 412.000 US-Dollar in den Schutz geistigen Eigentums und die Aufrechterhaltung von Patenten.

• Kosten für die Patentanmeldung: 187.000 US-Dollar
• Gebühren für die Verlängerung des Patents: 225.000 US-Dollar

Gehälter für wissenschaftliches Personal

Der gesamte Personalaufwand für wissenschaftliches Personal belief sich im Jahr 2023 auf 2.345.000 US-Dollar.

Personalkategorie	Jährliche Gehaltsausgaben ($)
Forschungswissenschaftler	1,450,000
Spezialisten für klinische Forschung	895,000

Einhaltung gesetzlicher Vorschriften und Dokumentation

Die Kosten für die Einhaltung gesetzlicher Vorschriften beliefen sich im Jahr 2023 auf 678.000 US-Dollar und umfassten Dokumentation, Einreichungen und behördliche Konsultationen.

• Vorbereitung der behördlichen Einreichung: 276.000 US-Dollar
• Compliance-Dokumentation: 402.000 US-Dollar

SciSparc Ltd. (SPRC) – Geschäftsmodell: Einnahmequellen

Potenzielle Verkäufe pharmazeutischer Produkte

Ab dem vierten Quartal 2023 meldete SciSparc Ltd. potenzielle Einnahmen aus der Entwicklung pharmazeutischer Produkte, die sich insbesondere auf Cannabinoid-basierte Behandlungen für neurologische Erkrankungen konzentrieren.

Produktkategorie	Geschätzter potenzieller Umsatz	Entwicklungsphase
SPR-101 (Alzheimer-Behandlung)	Voraussichtlich 3,2 Millionen US-Dollar	Klinische Studien der Phase II
SPR-CBD (Neurologische Störungen)	2,7 Millionen US-Dollar Potenzial	Präklinische Forschung

Lizenzierung proprietärer Forschungstechnologien

SciSparc Ltd. generiert Einnahmen durch die Lizenzierung seiner proprietären Cannabinoid-basierten Forschungstechnologien.

• Einnahmen aus Technologielizenzen: 450.000 US-Dollar im Jahr 2023
• Portfolio an geistigem Eigentum: 7 aktive Patente
• Durchschnittliche Lizenzgebühr: 65.000 USD pro Technologie

Forschungsstipendien und Finanzierung

Das Unternehmen sichert sich Forschungsgelder aus verschiedenen Quellen.

Finanzierungsquelle	Zuschussbetrag	Jahr
National Institutes of Health (NIH)	1,2 Millionen US-Dollar	2023
Private Forschungsstiftungen	$750,000	2023

Verbundforschungspartnerschaften

SciSparc Ltd. generiert Einnahmen durch strategische Forschungskooperationen.

• Anzahl aktiver Partnerschaften: 4
• Gesamtertrag aus der Verbundforschung: 1,5 Millionen US-Dollar im Jahr 2023
• Durchschnittlicher Partnerschaftswert: 375.000 $

Monetarisierung von geistigem Eigentum

Das Unternehmen monetarisiert sein geistiges Eigentum über verschiedene Kanäle.

IP-Monetarisierungsmethode	Generierter Umsatz	Leistung 2023
Patentverkäufe	$250,000	2 Patente verkauft
Lizenzvereinbarungen	$350,000	3 aktive Lizenzverträge

SciSparc Ltd. (SPRC) - Canvas Business Model: Value Propositions

You're looking at the core offerings that SciSparc Ltd. (SPRC) is putting forward to the market as of late 2025. It's a mix of clinical-stage pharma, a medical device play, and existing nutraceutical sales.

Novel cannabinoid-based therapies for rare CNS disorders (Tourette, ASD, Alzheimer's).

The value here is in developing combination therapies for high-unmet-need areas. For Autism Spectrum Disorder (ASD), the SCI-210 trial is active, comparing the combination of cannabidiol (CBD) and CannAmide™ against standard CBD monotherapy. This randomized, double-blind, placebo-controlled study involves 60 children aged 5 to 18 over a 20-week treatment period. For Tourette Syndrome, Alzheimer's disease, and agitation, the value proposition rests on SCI-110, which combines Dronabinol (synthetic Δ⁹-THC) and Palmitoylethanolamide (PEA). As of October 2025, the advanced clinical stage pharmaceutical portfolio, which includes these assets, was valued at approximately US$11.6 million.

Here's a quick look at the key cannabinoid assets:

Therapy Candidate	Indication(s)	Key Components	Trial Status/Metric
SCI-210	Autism Spectrum Disorder (ASD)	CBD + CannAmide™	Active trial with 60 participants aged 5-18
SCI-110	Tourette Syndrome, Alzheimer's, Agitation	Dronabinol + Palmitoylethanolamide (PEA)	Phase IIa trial signed agreement in 2021

Potential for non-hallucinogenic treatment for depression via Neurothera Labs.

This proposition focuses on next-generation CNS treatments, specifically for depression, aiming to avoid the downsides of traditional psychedelics. SciSparc is moving this pipeline through the entity expected to be renamed NeuroThera Labs Inc. following a late 2025 transaction. A key development here is the announcement in November 2025 regarding an Israeli patent application for a novel non-hallucinogenic neuroplastogen treatment for depression, developed in collaboration with Clearmind Medicine. Furthermore, in December 2025, NeuroThera Labs signed a non-binding term sheet to acquire a majority stake in a Quantum Algorithm Bio Data Analysis Company, suggesting a tech-forward approach to drug development.

Minimally invasive medical device (MUSE system) for the GERD market.

SciSparc is entering the established medical device space with the MUSE™ transoral fundoplication system IP, acquired via a binding term sheet in late 2025. This offers immediate access to a large, growing market. The global GERD device market was valued at approximately $2.5 billion in 2024, and is projected to reach $3.03 billion by 2030, showing a Compound Annual Growth Rate (CAGR) of 3.24% from 2025 to 2030. The deal structure involves issuing ordinary shares representing 19.99% of SciSparc's issued and outstanding capital. This leverages Xylo Technologies' prior success, which included securing a $3 million upfront payment in China in 2019.

Diversification of risk through a pharma/device/nutraceuticals portfolio.

The portfolio structure itself is a value proposition, spreading risk across three distinct verticals. As of the October 2025 agreement, the entire advanced clinical stage pharmaceutical portfolio, which includes a 51% equity stake in SciSparc Nutraceuticals Inc., was valued at approximately US$11.6 million. The company's TTM revenue as of September 30, 2025, was $1.31M, which was up 187.98% year-over-year. This contrasts with the TTM revenue of $1.306 million reported for the year ending December 31, 2024. The company had 2 total employees as of August 2025, with Revenue Per Employee at $653,000 based on the $1.31M TTM revenue figure.

Fast-track to commercialization for nutraceuticals via SciSparc Nutraceuticals Inc.

SciSparc Nutraceuticals Inc. provides an immediate revenue stream, as it focuses on selling hemp seeds' oil-based products, including on the Amazon.com Marketplace. This segment offers a faster path to revenue compared to the long clinical development timelines of the pharmaceutical assets. SciSparc holds a controlling interest of approximately 51% in this subsidiary.

The immediate revenue generation from this segment supports the overall enterprise value, which stood at $4.04 million as of December 2025, against a Market Cap of $2.97 million.

• Nutraceuticals revenue stream provides immediate cash flow.
• SciSparc owns a 51.0% controlling interest in the subsidiary.
• TTM Revenue as of September 30, 2025, was $1.31M.

SciSparc Ltd. (SPRC) - Canvas Business Model: Customer Relationships

You're managing a clinical-stage pharmaceutical company, so your relationships with key stakeholders are highly specialized, moving from deep scientific collaboration to strict financial oversight. Here's how SciSparc Ltd. (SPRC) structures these interactions as of late 2025.

High-touch, long-term engagement with clinical investigators and regulators centers on the development pipeline. Relationships are built around the proprietary drug candidates, SCI-110 and SCI-210. SCI-110 is in clinical trials for Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's Disease, and Agitation, while SCI-210 is being investigated for Autism Spectrum Disorder and Status Epilepticus. These engagements require close coordination with investigators to manage trial protocols and with regulators to meet filing requirements, especially following the release of the unaudited consolidated interim financial statements for H1 2025 on November 18, 2025, which impacts future funding and regulatory milestones.

Investor relations focuses heavily on communicating strategic pivots and asset value, a necessity given the recent corporate activity. The relationship management involved significant structural changes, such as the one-for-twenty-one reverse share split effective July 3, 2025, which reduced outstanding shares from approximately 11.2 million to about 534,600. The stock performance on November 28, 2025, at $2.20 USD, with a trading volume of 432.5k, is a constant point of communication. Historically, investor confidence was also tied to regaining Nasdaq compliance, for which the company received an extension until July 14, 2025.

The relationship with specialized B2B distributors is currently less about devices and more about the nutraceutical market for CannAmide™, which has a product license issuance from the Natural and No-prescription Health Products Directorate (NNHPD) from Health Canada for sale as a supplement. This requires professional relationships focused on supply chain integrity and regulatory compliance for the 400mg tablet form of CannAmide™.

Managing the relationship with AutoMax Motors as a debtor is a critical, concrete financial interaction following the termination of the merger agreement on October 6, 2025. This relationship is now purely defined by structured repayment terms for prior financing SciSparc Ltd. extended.

Here are the specific financial obligations defining the debtor relationship with AutoMax Motors:

• Total principal amount of loans outstanding: $6.25 million.
• Market capitalization of SciSparc Ltd. as of October 6, 2025: $7.71 million.
• The $4.25 million loan carries 9% per annum interest.
• The $2.0 million loan carries 8% annual interest.

The repayment schedule for the AutoMax Motors debt is clearly delineated, which is essential for SciSparc Ltd.'s cash flow planning:

Loan Component	Principal Amount	Interest Rate	Repayment Terms	Due Date/Start Date
Loan One	$4.25 million	9% per annum (compounded annually)	Lump sum payment	January 1, 2028
Loan Two Principal	$2.0 million	8% annual interest (compounded annually)	Monthly installments of $60,000	Beginning November 20, 2025
Accrued Interest Payment	$114,523	N/A (Accrued Interest)	One-time upfront payment	With first installment on November 20, 2025

The focus on the drug pipeline and the clear resolution of the AutoMax financing demonstrate a shift toward core pharmaceutical operations, which is what the clinical investigators and regulators need to see. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Channels

You're looking at how SciSparc Ltd. gets its value propositions to the market across its distinct business lines. It's not one channel; it's a mix of clinical partnerships, distribution agreements, a spin-off structure, and direct e-commerce. Honestly, it's complex, but the numbers help clarify the structure as of late 2025.

Clinical trial sites for drug development and data generation

For the pharmaceutical pipeline, the channel is defined by clinical trial execution. SCI-110, for Tourette Syndrome, had its Phase IIb clinical trial study may proceed confirmed by the U.S. Food and Drug Administration (FDA) as of September 30, 2024. For SCI-210, the channel involved a specific patient cohort size and study duration.

• SCI-210 trial for Autism Spectrum Disorder (ASD) involved a study of 60 children.
• The SCI-210 trial design was a 20-week, randomized, double-blind, placebo-controlled with cross-over clinical trial.
• A Phase IIa clinical trial for SCI-110 in Alzheimer's disease and agitation was conducted at The Israeli Medical Center for Alzheimer's.

Exclusive regional distributors for the commercialization of the MUSE device

SciSparc Ltd. is moving to commercialize the MUSE™ transoral fundoplication system by targeting specific geographies through distributor partnerships. This channel aims to tap into the global GERD device market, which was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030.

Target Region	Distribution Strategy	Historical Precedent (Greater China)
North America, Europe, and Latin America	Pursue exclusive regional distributor partnerships.	Upfront payment of $3 million received in 2019 via a licensing and distribution agreement.
Global GERD Device Market CAGR (2025-2030)	Expected growth rate of 3.24%.	Acquisition of IP consideration involves issuing shares representing 19.99% of issued and outstanding share capital.

The company plans to replicate the proven upfront licensing model. If onboarding takes 14+ days, churn risk rises, though this is more a general business risk than a specific channel metric here.

Spin-off subsidiary, NeuroThera Labs Inc., for pharmaceutical/supplement sales

SciSparc channels its advanced clinical portfolio and a portion of its nutraceutical business through its majority-owned subsidiary, NeuroThera Labs Inc. (TSXV: NTLX). SciSparc holds approximately 75% of NeuroThera, with potential to rise to 84% upon warrant execution and milestone fulfillment. The enterprise value of NeuroThera was pegged at about $3.3 million, including approximately $1.0 million in cash, at the October 2025 closing.

Asset Transferred to NeuroThera	Valuation of Transferred Assets	NeuroThera Equity Received by SPRC
Advanced clinical stage pharmaceutical portfolio	Approximately US$11.6 million.	63,300,000 common shares.
Equity stake of approximately 51% in SciSparc Nutraceuticals Inc.	Part of the US$11.6 million aggregate value.	4,000,000 Payment Warrants (exercisable at CAD 0.25 until October 22, 2030) and up to 48,000,000 contingent rights.

Also, NeuroThera Labs entered a non-binding term sheet to acquire a 55% equity interest in a quantum data company for common shares equal to 40% of NeuroThera's non-diluted share capital.

Amazon.com Marketplace for hemp seed oil-based nutraceutical products

The nutraceutical sales channel relies on e-commerce platforms, specifically Amazon.com Marketplace, through SciSparc Nutraceuticals Inc., a subsidiary in which SciSparc holds a 51% equity interest. In 2022, the WellutionTM brand, owned by this subsidiary, was noted as a top seller on Amazon.com Marketplace with over 40,000 product reviews. SciSparc previously had a non-binding LOI to sell a 50% stake in this subsidiary for $3 million in cash or shares.

• Exclusive license granted for CannAmide™ sales on the Amazon.com marketplace in Canada.
• WellutionTM brand had over 40,000 product reviews as of December 2022.
• The non-binding sale price for a 50% stake in the subsidiary was $3 million.

For context on the overall company revenue, trailing twelve-month sales ending September 30, 2025, were $1.31M, and the company reported having 2 employees. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Customer Segments

You're looking at the customer base for SciSparc Ltd. (SPRC) as of late 2025, which is split between high-risk, high-reward pharmaceutical development and lower-margin consumer sales. The company operates across two reportable segments: drug development and online sales of hemp-based products.

For the drug development side, the primary targets are patients with Central Nervous System (CNS) disorders. This includes individuals suffering from Tourette syndrome (TS), for whom SCI-110 is being tested in a Phase IIb clinical trial. Historically, the TS market was projected to reach $98.7M by 2023. Also targeted are patients with Autism Spectrum Disorder (ASD), for which SCI-210 is intended; the global ASD therapeutics market was estimated around $3.3B in 2018, with a projection to hit $4.6B by 2026. Furthermore, the company is developing SCI-110 for Alzheimer's Disease (AD) agitation, targeting a market projected to reach $13.6B by 2027 from a 2019 value of $7.4B.

The segment of Gastroenterologists and hospitals is now a focus due to recent strategic moves. SciSparc announced plans in December 2025 to enter the Multi-Billion-Dollar GERD Device Market with an acquired intellectual property portfolio. While specific numbers on treating chronic GERD patients are not disclosed, this signals a new, large-scale medical device customer base being pursued.

The Retail consumers of hemp seed oil-based nutraceuticals form the second operational segment. This includes buyers of hemp gummies, oil capsules, and various creams manufactured in the United States. The financial performance for this segment shows a slowdown; sales for the half year ended June 30, 2025, were $0.461 million, down from $0.84 million in the prior year period. The trailing twelve months (TTM) revenue ending September 30, 2025, was $1.31 million.

Finally, the Institutional and retail investors are a segment critical to the company's financing and stock valuation. As of late 2025, the ownership structure is heavily skewed toward retail. Institutional ownership sits at a low 0.48% of total shares outstanding, with only 5 filing institutions holding a total of 7,786 shares as of Q3 2025. Conversely, retail investors hold roughly 78.00% of the company's shares. The stock price on December 4, 2025, was $1.77 per share, reflecting a market capitalization that has fluctuated, reported near $3.93 million or $5.73 million in recent filings.

Here's a quick look at the scale of the markets SciSparc Ltd. is targeting or currently serving, based on the latest available data:

Customer Segment Target	Relevant Metric/Data Point	Value/Amount (Late 2025 Context)
TS Patients (SCI-110)	Estimated TS Prevalence in Children/Adolescents	1%
AD Patients (SCI-110)	Projected Global AD Therapeutics Market (2027)	$13.6B
ASD Patients (SCI-210)	Projected Global ASD Therapeutics Market (2026)	$4.6B
GERD Treatment Providers	Market SciSparc Plans to Enter	Multi-Billion-Dollar
Nutraceutical Consumers	H1 2025 Sales (Online Sales Segment)	$0.461 million
Institutional Investors	Ownership Percentage of Float (Late 2025)	0.48%

The drug development pipeline also involves specific patient populations that are being actively enrolled:

• Patients with Tourette Syndrome (TS) enrolled in Phase IIb trial.
• Adult patients (ages 18 to 65) for the SCI-110 TS trial.
• Patients with Alzheimer's disease and agitation.
• Children suffering from Autism Spectrum Disorder (ASD).

For the pharmaceutical segment, the potential for future licensing or acquisition is underpinned by the company's intellectual property portfolio, which includes 9 patent families with 8 granted patents (5 in the U.S.) and additional pending applications. Furthermore, the company recently announced a non-binding term sheet with Neurothera Labs in November 2025 regarding a novel neuroplastogen treatment.

SciSparc Ltd. (SPRC) - Canvas Business Model: Cost Structure

You're looking at the cost side of SciSparc Ltd.'s operations as of late 2025, and honestly, the numbers show a company heavily invested in its pipeline, which is typical for a clinical-stage biotech, but it's burning cash fast. The primary cost drivers are clearly centered around advancing its drug candidates through trials and maintaining the corporate structure needed to manage that science.

The most immediate financial pressure point is the bottom line. SciSparc Ltd. reported a net loss of $9.33 million for the first half of 2025. This loss is substantially higher than the $3.44 million net loss reported for the same period last year, signaling an increase in the cost base relative to revenue, which itself dropped to $0.461 million for H1 2025. That's a major gap to bridge.

The structure of these expenses points directly to the required clinical focus. You see high research and development (R&D) expenses for clinical trials dominating the operational spend. This R&D is the engine, but it's expensive to run, especially when dealing with central nervous system disorder therapies leveraging cannabinoid pharmaceuticals.

Also significant are the general and administrative (G&A) costs for corporate overhead. These cover everything from legal compliance for being listed on Nasdaq to the basic running of the headquarters. When you look at the trailing twelve months (TTM) data available near the end of 2025, the operating expenses are substantial, which is where both R&D and G&A reside.

Here's a quick look at the major operating cost components based on the latest available TTM figures, which give you a clearer picture of the ongoing burn rate:

Cost Component (TTM)	Amount (Millions USD)
Research & Development Expenses	$1.9
Selling, General & Admin Expenses	$6.04
Total Operating Expenses	$7.94

The costs associated with M&A activities and corporate restructuring are also a factor, though perhaps less consistent than R&D. You saw SciSparc Ltd. announce the mutual termination of its Merger Agreement with AutoMax Motors effective October 6, 2025. While the termination itself might involve certain wind-down costs, the prior agreement involved loan structures, such as a $2.0 million loan repayment schedule starting November 20, 2025, with 8% per annum interest, plus an upfront accrued interest payment of $114,523.

Finally, the fixed element of the cost structure involves the human capital required to execute the strategy. The salaries and fees for the specialized scientific and management team are a non-negotiable cost. These experts in cannabinoid pharmaceuticals and CNS disorders command high fees, which are bundled into the G&A and R&D lines. For instance, in a recent period, the company reported having an employee count of 2, with Profits Per Employee at -$3.24M, underscoring the high cost relative to current revenue generation.

You should focus your near-term review on the burn rate implied by these figures. If onboarding takes 14+ days, churn risk rises, but for SciSparc Ltd., the immediate risk is the cash depletion rate given the $9.33 million loss in just six months. Finance: draft 13-week cash view by Friday.

SciSparc Ltd. (SPRC) - Canvas Business Model: Revenue Streams

You're looking at how SciSparc Ltd. is bringing in cash right now, which is a mix of legacy operations, asset monetization, and future potential from recent deals. Honestly, the current picture shows minimal product sales, which is typical for a company focused on clinical-stage drug development. For the first half of 2025, SciSparc Ltd. reported product sales of $0.461 million.

A significant, one-time cash infusion came from divesting a non-core asset. SciSparc Ltd. closed the sale of its majority-owned subsidiary, MitoCareX Bio Ltd., to N2OFF, Inc. on October 20, 2025. From this, SciSparc Ltd. received $700,000 in cash for the sale of 6,622 MitoCareX shares. This transaction immediately boosted liquidity, though it means SciSparc Ltd. no longer holds majority control over MitoCareX.

The resolution of the planned merger with AutoMax Motors Ltd. on October 6, 2025, established clear, near-term, and long-term debt repayment streams that are now central to SciSparc Ltd.'s non-product revenue. This is a crucial shift in cash flow visibility.

Here's a quick look at the concrete financial components driving the current and near-term revenue picture for SciSparc Ltd.:

Revenue Component	Amount/Term	Date/Frequency	Source Reference
H1 2025 Product Sales	$0.461 million	Period ending June 30, 2025	As specified
MitoCareX Asset Sale (Cash)	$700,000	October 20, 2025 (One-time)
AutoMax Loan Repayment (Initial Interest)	$114,523	Upfront payment (Nov 20, 2025)
AutoMax Loan Repayment (Installment Principal)	$60,000 per month	Starting November 20, 2025
AutoMax Loan Repayment (Final Principal)	$4.25 million	January 1, 2028 (Lump Sum)

Looking further out, the intellectual property (IP) strategy is designed to generate future, potentially high-margin revenue, primarily through licensing and milestone payments. SciSparc Ltd. is positioning itself to replicate a successful model for its newly acquired MUSE GERD device IP.

The potential for future revenue from licensed IP and spin-offs is substantial, particularly from the N2OFF transaction:

• Sellers (including SciSparc Ltd.) are entitled to 30% of N2OFF's financing proceeds, capped at $1.6 million over five years.
• Potential milestone-based issuances of up to 25% of N2OFF common stock.

The commercialization of the MUSE GERD device represents a major potential revenue stream by entering a growing market. SciSparc Ltd. intends to pursue global commercialization through exclusive regional distribution partnerships, mirroring Xylo Technologies' prior success.

The market opportunity for the MUSE system is quantified by external analysis:

• Global GERD device market value in 2024 was approximately $2.5 billion.
• Projected market value by 2030 is $3.03 billion.
• This represents a Compound Annual Growth Rate (CAGR) of 3.24% from 2025 to 2030.

To be fair, the upfront payment SciSparc Ltd. hopes to replicate was $3 million received by Xylo for Greater China commercialization in 2019. Finance: draft 13-week cash view by Friday.